Volume 39, Pages (January 2003)

Slides:

Advertisements

Similar presentations

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

Advertisements

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep

Volume 63, Issue 1, Pages (July 2015)

Volume 46, Issue 3, Pages (March 2007)

The impact of hepatitis E in the liver transplant setting

Evangelos Cholongitas, George V. Papatheodoridis, Andrew K. Burroughs

Volume 50, Issue 4, Pages (April 2009)

Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges Marie-Louise Michel, Qiang Deng,

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review Christian Thoma, Christopher P. Day, Michael.

An integration of deep viral suppression with sequential immune modulation (cocktail therapy) to restore antiviral capacity: The future of chronic hepatitis.

Volume 67, Issue 2, Pages (August 2017)

R. Cavallo Clinical Microbiology and Infection

Evolution of the incidence of hepatitis B virus infection and immunization rates in a large French cohort born between 1960 and 1994 C. Ramière, L. Roche,

Volume 39, Issue 6, Pages (December 2003)

Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar

The impact of hepatitis E in the liver transplant setting

Matthew T. Kitson, Stuart K. Roberts Journal of Hepatology

NS5A inhibitors in the treatment of hepatitis C

التهاب الكبد الوبائي Viral Hepatitis

A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update Emmet B. Keeffe, Douglas T. Dieterich,

Leptin, obesity, and liver disease

Volume 42, Issue 5, Pages (May 2005)

Immigration and viral hepatitis

Volume 123, Issue 6, Pages (December 2002)

Hepatitis B and C virus-related carcinogenesis

Infectious causes of cancer: an evolving educational saga

Virological tools to diagnose and monitor hepatitis C virus infection

Natural history of hepatitis B

Ype P. de Jong, Charles M. Rice, Alexander Ploss Journal of Hepatology

Liver transplantation for hepatitis B virus-related liver disease: Indications, prevention of recurrence and results Bruno Roche, Didier Samuel Journal.

Introduction The American Journal of Medicine

Volume 69, Issue 2, Pages (August 2018)

Volume 44, Pages S19-S24 (January 2006)

Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection Anaïs Vallet-Pichard,

How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach? Neil Rajoriya,

Evangelos Cholongitas, George V. Papatheodoridis, Andrew K. Burroughs

American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive.

Chronic HCV infection and the clonality of intrahepatic T cells

Hepatitis C core protein – The “core” of immune deception?

Jean-Michel Pawlotsky Gastroenterology

Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges Marie-Louise Michel, Qiang Deng,

Hepatocyte-like cells differentiated from human induced pluripotent stem cells (iHLCs) are permissive to hepatitis C virus (HCV) infection: HCV study.

Marc van der Valk, Hans L. Zaaijer, Arnon P. Kater, Janke Schinkel

Combination therapy with lamivudine and famciclovir for chronic hepatitis B infection Hong Shen, Mazen Alsatie, George Eckert, Naga Chalasani, Lawrence.

Volume 68, Issue 3, Pages (March 2018)

Genomic risk of hepatitis C-related hepatocellular carcinoma

Autophagy in the liver Journal of Hepatology

Prevalence and Challenges of Liver Diseases in Patients With Chronic Hepatitis C Virus Infection Ira M. Jacobson, Gary L. Davis, Hashem El–Serag, Francesco.

Hepatitis C virus and interferon type III (interferon-λ3/interleukin-28B and interferon-λ4): genetic basis of susceptibility to infection and response.

Stephen Locarnini, Angelos Hatzakis, Ding-Shinn Chen, Anna Lok

Economics of chronic hepatitis B and hepatitis C

Volume 42, Issue 4, Pages (April 2005)

Hepatitis B and C virus-related carcinogenesis

EASL Clinical Practice Guidelines on hepatitis E virus infection

A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update Emmet B. Keeffe, Douglas T. Dieterich,

Volume 50, Issue 4, Pages (April 2009)

Antibacterial drug discovery in the 21st century

EASL Clinical Practice Guidelines: Management of chronic hepatitis B

Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong

Prevalence and Treatment of Hepatitis C Virus Genotypes 4, 5, and 6

Volume 56, Issue 6, Pages (June 2012)

H. Leblebicioglu, C. Eroglu Clinical Microbiology and Infection

Immigration and viral hepatitis

Ten-year follow-up of hepatitis B relapse after cessation of lamivudine or telbivudine treatment in chronic hepatitis B patients H.-Y. Pan, H.-Y. Pan,

Volume 63, Issue 1, Pages (July 2015)

Volume 51, Issue 2, Pages (August 2009)

Christos Konstantakis, Maria Karamesini, Christos Triantos

Chimeric mouse model of hepatitis B virus infection

Scott K. Fung, Anna S.F. Lok Clinical Gastroenterology and Hepatology

Reversion of disease manifestations after HCV eradication

Presentation transcript:

Volume 39, Pages 151-159 (January 2003) Immunomodulatory drugs and therapeutic vaccine in chronic hepatitis B infection Pascal Lebray, Anaı̈s Vallet-Pichard, Marie-Louise Michel, Hélène Fontaine, Rodolphe Sobesky, Christian Bréchot, Stanislas Pol Journal of Hepatology Volume 39, Pages 151-159 (January 2003) DOI: 10.1016/S0168-8278(03)00336-2

Fig. 1 Immune responses associated with recovery or chronic disease after HBV infection. Journal of Hepatology 2003 39, 151-159DOI: (10.1016/S0168-8278(03)00336-2)

Fig. 2 Potential therapeutic approaches for the treatment of chronic HBV infection. Currently available treatments (interferon-α and lamivudine) can be combined with new specific immunotherapeutic approaches. Journal of Hepatology 2003 39, 151-159DOI: (10.1016/S0168-8278(03)00336-2)

Fig. 3 Summary of the immune effects obtained with the DNA based immunization to the HBsAg in mice [67]. Journal of Hepatology 2003 39, 151-159DOI: (10.1016/S0168-8278(03)00336-2)

Fig. 4 Summary of the therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein of duck hepatitis B virus infection [70]. Journal of Hepatology 2003 39, 151-159DOI: (10.1016/S0168-8278(03)00336-2)